Publicaciones recientes

 

1) Ácido hialurónico de bajo peso molecular como agente inmunomodulador de tumores gastrointestinales (Dra. Laura Alaniz, Ph.D. Investigadora Adjunta CONICET)

• Antitumor effects of hyaluronic acid inhibitor 4-Methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Piccioni F, Malvicini M, Garcia MG, Rodriguez A, Atorrasagasti C, Kippes N, Buena IT, Rizzo MM, Bayo J, Aquino J, Viola M, Passi A, Alaniz L, Mazzolini G. Glycobiology. 2011 Oct 28. [Epub ahead of print]
• Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma. Alaniz L, Rizzo M, Garcia MG, Piccioni F, Aquino JB, Malvicini M, Atorrasagasti C, Bayo J, Echeverria I, Sarobe P, Mazzolini G. Cancer Immunol Immunother. 2011 Oct;60(10):1383-95.
• Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Alaniz L, Rizzo M, Malvicini M, Jaunarena J, Avella D, Atorrasagasti C, Aquino JB, Garcia M, Matar P, Silva M, Mazzolini G. Cancer Lett. 2009 Jun 8;278(1):9-16.

• Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma. Aquino JB, Bolontrade MF, García MG, Podhajcer OL, Mazzolini G. Gene Ther. 2010 Jun;17(6):692-708.
• Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Adameyko I*, Lallemend F*, Aquino JB, Pereira JA, Topilko P, Müller T, Fritz N, Beljajeva A, Mochii M, Liste I, Usoskin D, Suter U, Birchmeier C, Ernfors P. Cell. 2009 Oct 16;139(2):366-79.
• The retinoic acid inducible Cas-family signaling protein Nedd9 regulates neural crest cell migration by modulating adhesion and actin dynamics. Aquino JB, Lallemend F, Marmigère F, Adameyko II, Golemis EA, Ernfors P. Neuroscience. 2009 Sep 15;162(4):1106-19.
• Differential expression and dynamic changes of murine NEDD9 in progenitor cells of diverse tissues. Aquino JB, Marmigère F, Lallemend F, Lundgren TK, Villar MJ, Wegner M, Ernfors P. Gene Expr Patterns. 2008 Apr;8(4):217-26.

Contacto:

Jorge B. Aquino, Ph.D. jaquino@cas.austral.edu.ar. Teléfono: 02322-482967.

3) Papel de las células estromales  mesenquimales de médula ósea en la conformación del estroma tumoral en el hepatocarcinoma (HCC) (Dra. Mariana G. García, Ph.D. Investigadora Adjunta CONICET)

• Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma. Aquino JB, Bolontrade MF, García MG, Podhajcer OL, Mazzolini G. Gene Ther. 2010 Jun;17(6):692-708.
• Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo. Garcia MG, Bayo J, Bolontrade MF, Sganga L, Malvicini M, Alaniz L, Aquino JB, Fiore E, Rizzo MM, Rodriguez A, Lorenti A, Andriani O, Podhajcer O, Mazzolini G. Mol Pharm. 2011 Oct 3;8(5):1538-48.

  ………………………………………………………..

4) SPARC (Secreted Protein, Acidic and Rich in Cysteine) e injuria hepática. (Dra. Catalina Atorrasagasti, Ph.D. CONICET)

• SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-β1 and PDGF. Atorrasagasti C, Aquino JB, Hofman L, Alaniz L, Malvicini M, Garcia M, Benedetti L, Friedman SL, Podhajcer O, Mazzolini G. Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G739-48.
• Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells. Atorrasagasti C, Malvicini M, Aquino JB, Alaniz L, Garcia M, Bolontrade M, Rizzo M, Podhajcer OL, Mazzolini G. Int J Cancer. 2010 Jun 1;126(11):2726-40.
• Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats. Camino AM, Atorrasagasti C, Maccio D, Prada F, Salvatierra E, Rizzo M, Alaniz L, Aquino JB, Podhajcer OL, Silva M, Mazzolini G. J Gene Med. 2008 Sep;10(9):993-1004.

Contacto:

Catalina Atorrasagasti, Ph.D. mcatalinaa@gmail.com. Teléfono: 02322-482695.

   

5) Modulación de la respuesta inmunitaria antitumoral mediante el tratamiento combinado con ciclofosfamida y terapia génica con Interleuquina-12 (IL-12) (Dra. Mariana Malvicini, Ph.D. CONICET)

• Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Malvicini M, Ingolotti M, Piccioni F, Garcia M, Bayo J, Atorrasagasti C, Alaniz L, Aquino JB, Espinoza JA, Gidekel M, Scharovsky OG, Matar P, Mazzolini G. Mol Oncol. 2011 Jun;5(3):242-55.
• A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Malvicini M, Rizzo M, Alaniz L, Piñero F, García M, Atorrasagasti C, Aquino JB, Rozados V, Scharovsky OG, Matar P, Mazzolini G. Clin Cancer Res. 2009 Dec 1;15(23):7256-65.
• Immunotherapy for liver tumors: present status and future prospects. Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G. J Biomed Sci. 2009 Mar 6;16:30.